



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Keith D. ALLEN et al.

Application No.: 10/010,065

Filed: December 5, 2001

For: Transgenic Mice Containing  
Glucagon Receptor Gene Disruptions

Examiner: Unassigned

Art Unit: 1645

Atty. Docket No.: R-648

PRELIMINARY AMENDMENT

RECEIVED  
JUL 26 2002  
TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to the examination of the above-referenced application and in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed June 19, 2002, entry of the following amendment is respectfully requested:

In the Drawings

Please replace Figure 2A in the application with the new Figure 2A enclosed herewith. A marked up copy of Figure 2A is also enclosed, with corrections indicated in red.

REMARKS

The amendment to Figure 2A merely adds a sequence identifier to the figure to comply with 37 C.F.R. 1.821(d) and does not introduce new matter. Entry of the foregoing amendment is respectfully requested.

Favorable action on the merits is earnestly solicited.

Date: July 16, 2002

Respectfully submitted,


  
Marjette A. Lapiz, Reg. No. 44,202

DELTAGEN, INC.  
740 Bay Road  
Redwood City, CA 94063  
(650) 569-5168

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8**

I hereby certify that this correspondence and its listed enclosures is being deposited with the United States Postal Service as First Class Mail, postage paid, in an envelope addressed to: Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231, Box NF Amendment/OIPE on July 16, 2002

Name: Deb rah A. M jarro

Signed: 

Date: July 16, 2002